Alan Wise

CEO
IOmet Pharma Ltd
Malta

Business Expert Microbiology
Biography

Alan joined IOmet Pharma five years ago, where he has focused on immuno-oncology and cancer metabolism. In particular, he is an expert on IDO1 and TDO, the kynurenine pathway and their ever-growing importance as exciting cancer immunotherapy targets. Alan, a biochemist by training, spent 12 years with GlaxoSmithKline, in a variety of program leadership roles spanning discovery and translation into clinic. Alan joined IOmet Pharma five years ago, where he has focused on immuno-oncology and cancer metabolism. In particular, he is an expert on IDO1 and TDO, the kynurenine pathway and their ever-growing importance as exciting cancer immunotherapy targets. Alan, a biochemist by training, spent 12 years with GlaxoSmithKline, in a variety of program leadership roles spanning discovery and translation into clinic.

Research Intrest

FERMENTATION